# A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

> **NCT03565900** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 277 (actual)

## Conditions studied

- Pneumococcal Infections

## Interventions

- **BIOLOGICAL:** V114
- **BIOLOGICAL:** Prevnar 13™
- **BIOLOGICAL:** PNEUMOVAX™23

## Key facts

- **NCT ID:** NCT03565900
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-12
- **Primary completion:** 2021-11-04
- **Final completion:** 2021-11-04
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03565900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03565900, "A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT03565900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*